In this study we profiled vaccine-induced polyclonal antibodies as well as plasmablast-derived
mAbs from individuals who received SARS-CoV-2 spike mRNA vaccine. Polyclonal …

Responses of Seropositive Persons to a Single SARS-CoV-2 Vaccine Some persons who
have recovered from Covid-19 have antibodies to the spike protein of SARS-CoV-2. In 43 …

It is concerning that emerging variants of SARS-CoV-2 can evade neutralising antibodies
induced by previous infection or vaccination through mutations in the spike protein, including …

COVID-19 mRNA vaccines are highly efficacious in preventing COVID-19 morbidity and
mortality in phase 3 clinical studies as well as in real-world settings. Emerging evidence …

Immune responses at the respiratory mucosal interface are critical to prevent respiratory
infections but it is unclear to what extent antigen specific mucosal secretory IgA (SIgA) …

Persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections have
been reported in immune-compromised individuals and people undergoing immune-…

Mucosal immune responses are critical to prevent respiratory infections but it is unclear to
what extent antigen specific mucosal secretory IgA (SIgA) antibodies are induced by mRNA …

Highly efficacious vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
have been developed. However, the emergence of viral variants that are more …

It is thought that mRNA-based vaccine-induced immunity to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) wanes quickly, based mostly on short-term studies. Here, …

The PARIS (Protection Associated with Rapid Immunity to SARS-CoV-2) cohort follows health
care workers with and without documented coronavirus disease 2019 (COVID-19) since …